Affiliation:
1. Laser & Skin Surgery Center of New York, New York, New York;
2. The Ronald O. Perelman Department of Dermatology, NYU Langone Health, New York, New York
Abstract
BACKGROUND
Patients frequently seek laser treatment for vascular conditions. More recently, a novel 532 and 1,064 nm laser was developed to offer greater flexibility.
OBJECTIVE
A prospective clinical trial evaluated the safety and efficacy of a novel, variable-sequenced, long-pulsed, 532 and 1,064 nm laser with cryogen spray cooling (DermaV, Lutronic, South Korea).
MATERIALS AND METHODS
Subjects with vascular conditions were enrolled for laser treatments. Clinical evaluations and optical coherence tomography (OCT) imaging were performed.
RESULTS
Thirteen subjects were enrolled. The mean age was 51.3 years, and 92.3% were women. Fitzpatrick skin types I–IV were included. Treatment indications included broken blood vessels, rosacea, port-wine birthmark, and spider angioma. For physician investigator grading, all subjects were graded as improved at both 30-day and 90-day follow-up. Blinded photographic review by 3 independent, blinded physicians had a mean of 89.7% of cases selected correctly with at least 2 of 3 in agreement for 100.0% of cases. Optical coherence tomography imaging showed significant reductions in vessel density (p = .018) and diameter (p = .003) of the superficial vascular plexus. No serious adverse events occurred.
CONCLUSION
A novel, variable-sequenced, long-pulsed, 532 and 1,064 nm laser with cryogen spray cooling can safely and effectively improve vascular conditions and lesions as determined by both clinical and OCT evaluation.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Dermatology,General Medicine,Surgery